Thiopurines (Azathioprine, Mercaptopurin) updated on 07-28-2025

Neonatal anemia

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S18477
R78399		 Yeaman (Controls mainly exposed to biologics), 2023 Neonatal Anemia (hemoglobin < 140 g/l) during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick excluded Adjustment: No Indications: Inflammatory Bowel disease (IBD) 0.50 [0.05;4.58] C
excluded (control group) 		1/19   5/50 6 19
ref
S18487
R78408		 Yeaman (Controls unexposed, disease free), 2023 Neonatal Anemia (hemoglobin < 140 g/l) during pregnancy (anytime or not specified) prospective cohort unexposed, disease free Adjustment: No Indications: Inflammatory Bowel disease (IBD) 0.36 [0.04;3.28] C 1/19   5/37 6 19
ref
S12241
R52637		 Koslowsky, 2019 Any abnormal index for anemia (Hemoglobin < 11, MCV < 72, RDW > 17.8%) throughout pregnancy prospective cohort unexposed, sick Adjustment: No Indications: Inflammatory Bowel disease (IBD) 2.05 [0.43;9.78] C 10/23   3/11 13 23
ref
Total 2 studies 1.03 [0.19;5.51] 19 42
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Yeaman (Controls unexposed, disease free), 2023Yeaman, 2023 1 0.36[0.04; 3.28]61939%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: unclearROB mesure: lowROB reporting: moderate Koslowsky, 2019Koslowsky, 2019 2.05[0.43; 9.78]132361%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 37% 1.03[0.19; 5.51]19420.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, disease free;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.03[0.19; 5.51]194237%NAYeaman (Controls unexposed, disease free), 2023 Koslowsky, 2019 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.36[0.04; 3.28]619 -NAYeaman (Controls unexposed, disease free), 2023 1 unexposed, sickunexposed, sick 2.05[0.43; 9.78]1323 -NAKoslowsky, 2019 1 Tags Adjustment   - No  - No 1.03[0.19; 5.51]194237%NAYeaman (Controls unexposed, disease free), 2023 Koslowsky, 2019 2 Indications   - Inflammatory Bowel disease (IBD)  - Inflammatory Bowel disease (IBD) 1.03[0.19; 5.51]194237%NAYeaman (Controls unexposed, disease free), 2023 Koslowsky, 2019 2 All studiesAll studies 1.03[0.19; 5.51]194237%NAYeaman (Controls unexposed, disease free), 2023 Koslowsky, 2019 20.15.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 18477

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) Out of scale0.36[0.04; 3.28]619 -NAYeaman (Controls unexposed, disease free), 2023 1 unexposed, sick controlsunexposed, sick controls 2.05[0.43; 9.78]1323 -NAKoslowsky, 2019 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls Out of scale0.50[0.05; 4.58]619 -NAYeaman (Controls mainly exposed to biologics), 2023 10.510.01.0